Cytokines in multiple sclerosis: methodological aspects and pathogenic implications.
about
Impact of Exercise on Innate Immunity in Multiple Sclerosis Progression and SymptomatologyExercise and disease progression in multiple sclerosis: can exercise slow down the progression of multiple sclerosis?Exercise in multiple sclerosis -- an integral component of disease management.Pain in experimental autoimmune encephalitis: a comparative study between different mouse models.Examining the evidence: complementary adjunctive therapies for multiple sclerosis.Stimulated PBMC-produced IFN-γ and TNF-α are associated with altered relapse risk in multiple sclerosis: results from a prospective cohort study.RETRACTED: Resistant Strains of Enterotoxigenic Staphylococcus aureus; Unknown Risk for Multiple Sclerosis Exacerbation.Simultaneous presentation of acute disseminated encephalomyelitis (ADEM) and systemic lupus erythematosus (SLE) after enteroviral infection: can ADEM present as the first manifestation of SLE?Anti-inflammatory cytokine gene therapy decreases sensory and motor dysfunction in experimental Multiple Sclerosis: MOG-EAE behavioral and anatomical symptom treatment with cytokine gene therapy.Inflammation in the spotlight-clinical relevance of genetic variants affecting nuclear factor κB and tumor necrosis factor receptor 1.Staphylococcus aureus harbouring Enterotoxin A as a possible risk factor for multiple sclerosis exacerbations.Tumor necrosis factor beta (TNF-β) NcoI polymorphism is associated with multiple sclerosis in Caucasian patients from Southern Brazil independently from HLA-DRB1.Synergistic immune responses induced by endogenous retrovirus and herpesvirus antigens result in increased production of inflammatory cytokines in multiple sclerosis patients.Prevalence of sea, seb, sec, sed, and tsst-1 genes of Staphylococcus aureus in nasal carriage and their association with multiple sclerosis.Cytokine responses to resistance training in people with multiple sclerosis.
P2860
Q26745562-D0F9729F-F769-46F6-AD3A-D6A358FFA020Q34204413-F9CCB497-FD92-4104-995A-5BBF9A53AD20Q36031826-1088A712-E675-4312-9076-B9576EB12FDBQ36639036-0412994D-3936-4DB1-BD29-D29AD69306A1Q37217845-749DDDBD-5510-4289-91D3-B65206920BE1Q39127014-7797FDED-1944-444F-943C-89581E7D7EE3Q40949416-5CC46D1C-0D0B-4425-898D-4B117DD59A69Q41609660-CF6D4CA7-5CD8-45BF-BA83-895155F403A4Q41789029-817CD5B9-3D2C-4B34-8AFB-7AAE033C5E56Q42344455-DF8FD14C-E733-4C80-A1F3-3AF8CCDFDAFBQ43416735-38CCEE31-F6C0-4F28-ACFE-9829F5B5D0F4Q43568427-58190ACF-D457-40DA-BE3D-DB0A23240189Q45261080-E73E5A4B-1411-4028-89BF-547FA79FCB37Q49633908-13E4C996-473F-4594-A9A1-807AA5C149B4Q51797343-1DAC0AC8-2832-4483-BAF8-4B3202E7853C
P2860
Cytokines in multiple sclerosis: methodological aspects and pathogenic implications.
description
2002 nî lūn-bûn
@nan
2002 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Cytokines in multiple sclerosis: methodological aspects and pathogenic implications.
@ast
Cytokines in multiple sclerosis: methodological aspects and pathogenic implications.
@en
Cytokines in multiple sclerosis: methodological aspects and pathogenic implications.
@nl
type
label
Cytokines in multiple sclerosis: methodological aspects and pathogenic implications.
@ast
Cytokines in multiple sclerosis: methodological aspects and pathogenic implications.
@en
Cytokines in multiple sclerosis: methodological aspects and pathogenic implications.
@nl
prefLabel
Cytokines in multiple sclerosis: methodological aspects and pathogenic implications.
@ast
Cytokines in multiple sclerosis: methodological aspects and pathogenic implications.
@en
Cytokines in multiple sclerosis: methodological aspects and pathogenic implications.
@nl
P2860
P1476
Cytokines in multiple sclerosis: methodological aspects and pathogenic implications.
@en
P2860
P304
P356
10.1191/1352458502MS837RR
P577
2002-10-01T00:00:00Z